Capecitabine-Induced Hand-Foot Syndrome With Genital Involvement
Overview
This case report details a 59-year-old male with pancreatic cancer who developed grade 2 hand-foot syndrome (HFS) with genital involvement after receiving capecitabine. The management included treatment interruption and topical therapies.
Background
Hand-foot syndrome (HFS) is a common dermatological toxicity associated with fluoropyrimidines like capecitabine, impacting patient quality of life and treatment adherence. The incidence of HFS can be significant, with rates reported between 54% to 60% (FDA, 2015a). This case highlights a unique presentation of HFS involving the genital area.
Data Highlights
No numerical data or trial data available in the provided source.
Key Findings
- The patient developed grade 2 HFS characterized by skin dryness, cracking, and ulceration after two cycles of capecitabine.
- Genital involvement included severe pain and discomfort, rated 10/10.
- After treatment interruption and topical management, genital symptoms improved significantly.
- Palmar-plantar erythrodysesthesia (PPE) remained at grade 1.
Clinical Implications
Healthcare providers should be vigilant for signs of HFS, including genital involvement, in patients receiving capecitabine. Early intervention with topical treatments may alleviate symptoms and improve patient comfort.
Conclusion
This case illustrates the potential for capecitabine to cause significant dermatological toxicities, including genital HFS.
Related Resources & Content
- Erythrodysesthesia of the Penile-Scrotal Area in Rectal Cancer Patients Undergoing Fluoropyrimidine-Based Chemoradiation: A Series of Case Reports, 2024
- What Prevents Chemo-Linked HFS?, conexiant
- Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study, Frontiers in Medicine, 2026
- Prevention and Treatment of Multikinase Inhibitor–induced Hand-Foot Syndrome, The ASCO Post
- FDA Label for Capecitabine, 2025
- label
- https://www.ons.org/system/files/journal-article-pdfs/SkinToxGuidelineSupplementaryMaterial.pdf
- Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial | Journal of Clinical Oncology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
